Quick Answer
Stoke Therapeutics, Inc. reported Shares Outstanding of 58.92 million shares for fiscal year 2025.
Stoke Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 58.92M | +9.0% |
| 2024 | 54.03M | +17.7% |
| 2023 | 45.92M | +16.4% |
| 2022 | 39.44M | +6.9% |
| 2021 | 36.90M | +0.9% |
| 2020 | 36.58M | +11.3% |
| 2019 | 32.86M | +4417.6% |
| 2018 | 727,413 | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 55.12M | +4.1% | +0.7% |
| June 30, 2025 | 54.72M | +4.6% | +0.2% |
| March 31, 2025 | 54.60M | +17.4% | +1.0% |
| December 31, 2024 | 54.03M | +17.7% | +2.1% |
| September 30, 2024 | 52.94M | +19.5% | +1.2% |
| June 30, 2024 | 52.31M | +18.3% | +12.5% |
| March 31, 2024 | 46.50M | +5.3% | +1.3% |
| December 31, 2023 | 45.92M | +16.4% | +3.7% |
- Stoke Therapeutics, Inc. showed an increase of +9.0% in Shares Outstanding compared to the prior fiscal year.
- Over the 2018–2025 period, Stoke Therapeutics, Inc.’s shares outstanding has grown by 8000.2% (from 727.4 thousand shares to 58.92 million shares).
- The most recent figure is from Stoke Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: